Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Current Leases (2019 - 2025)

Heron Therapeutics (HRTX) has disclosed Current Leases for 7 consecutive years, with $780000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Leases fell 75.99% year-over-year to $780000.0, compared with a TTM value of $780000.0 through Sep 2025, down 75.99%, and an annual FY2024 reading of $3.0 million, down 1.24% over the prior year.
  • Current Leases was $780000.0 for Q3 2025 at Heron Therapeutics, down from $1.5 million in the prior quarter.
  • Across five years, Current Leases topped out at $3.3 million in Q3 2021 and bottomed at $780000.0 in Q3 2025.
  • Average Current Leases over 5 years is $2.7 million, with a median of $2.8 million recorded in 2023.
  • The sharpest move saw Current Leases rose 23.8% in 2024, then plummeted 75.99% in 2025.
  • Year by year, Current Leases stood at $2.4 million in 2021, then grew by 11.46% to $2.7 million in 2022, then grew by 14.14% to $3.1 million in 2023, then fell by 1.24% to $3.0 million in 2024, then tumbled by 74.32% to $780000.0 in 2025.
  • Business Quant data shows Current Leases for HRTX at $780000.0 in Q3 2025, $1.5 million in Q2 2025, and $2.3 million in Q1 2025.